1. Introduction {#sec0005}
===============

According to the United Nations, the world population will increase to 9 billion by 2050. The demand for animal-derived food, which has been growing at a rate of \>7% over the last two decades, will correspondingly increase, both in developed and developing countries (FABRE Technology Platform working group). Therefore, going forward, to support this population growth, we need to secure a sustainable means of producing the quantity of food required, and we need to do this in a safe and ethical manner to protect the consumer, the health and welfare of animals and our environment ([@bib0215]).

This global population growth will open up attractive market prospects for countries with the capacity and technology to produce large quantities of high-quality animal products (particularly beef, dairy, pig and sheep). The value of farm-level animal production to the EU is over €130 billion; farmers represent \>8% of the workforce, and farms employ \>15 million people ([@bib0185]). As farming intensifies, however, issues surrounding disease control, the prevention of disease transmission from animals to humans (zoonosis), the health and welfare of animals and the quality/safety of the food we consume will come to the forefront ([@bib0185]; Meat & Livestock Australia: [http://www.mla.com.au](http://www.mla.com.au/){#intr0005}).

Ireland is a good example of a small European country whose economy depends heavily on agriculture and at the same time has the ability to take advantage of these future trends. Irish agriculture is primarily a grass-based industry; of the total land area of 6.9 million hectares, 4.2 million (64%) is devoted to agriculture, 90% of which is pasture. There are about 6.5 million cattle in Ireland and the Irish sheep flock exceeds 4.8 million head, with a breeding flock of 2.51 million head. During 2011, 548,000 tonnes of beef and 37,000 tonnes of sheep meat were produced, most of which was exported. Each year, 17,000 dairy farms produce 5.4 billion litres of milk (Teagasc). These figures provide a snapshot of how important the livestock industry, altogether valued at €5--6 billion per annum, can be to a small economy such as Ireland\'s with a population of under 5 million ([@bib0055]).

2. Parasitic diseases impact hugely on the animal production industry {#sec0010}
=====================================================================

Helminth parasites cause \>55% of all farm animal diseases in Europe and effective control strategies would have a major impact on the sustainability of the livestock industry ([@bib0420; @bib0410; @bib0390]). In Europe, parasitic diseases of farm animals are caused principally by infections with the liver fluke Fasciola hepatica, the lungworm *Dictyocaulus viviparus*, and the gastrointestinal nematode parasites of sheep (*Haemonchus contortus*, *Teladorsagia circumcincta*) and cattle (*Ostertagia ostertagi*, *Cooperia oncophora*). These parasites impact on livestock productivity by affecting growth rates, fertility and the quality of wool and milk production. In particular, during seasons of major fluke outbreaks, infection can result in many animal fatalities ([@bib0480]). In general, about 17% of animal production is estimated to be lost through infection of livestock with pathogens including these parasites ([@bib0185]).

The losses to the livestock industry as a result of parasitic helminths are compounded by the significant effort and cost of trying to control these infections with regular chemical treatments. Within Europe, the annual spend on anthelmintic drugs for parasitic helminths of ruminants has been estimated to be €400 million ([@bib0560; @bib0390]). These costs contribute to the overall economic losses related to disease, which for *F. hepatica*, in particular, are estimated to be US \$3 billion globally ([@bib0585; @bib0340; @bib0480]). However, anthelmintic resistance, especially in gastrointestinal nematode parasites ([@bib0300]), has spread to the point that it is now a global concern and is already impacting significantly on livestock productivity in many regions. Resistance is also becoming a serious issue in liver fluke ([@bib0190; @bib0120]). The use of chemical products to control parasitic infections is, therefore, not sustainable in the long term because of the likelihood of continual emergence of drug-resistant parasite populations. Additionally, there are growing consumer concerns about chemical residues in food, and also the detrimental impact they have on the environment ([@bib0115; @bib0100]). In particular, an assessment report adopted by the Committee for Medicinal Products for Veterinary Use (European Commission) has recently established maximum residue limits for triclabendazole (TCBZ) in bovine and ovine milk, in addition to those already set for ruminant muscle, fat, liver and kidney ([@bib0180]). Recent flukicide licensing restrictions for lactating dairy cows only allow the use of albendazole (ABZ) and oxyclosanide (OCZ) for fluke control ([@bib0255]). Unlike TCBZ which is active against both immature and adult parasites, ABZ and OCZ have restrictive activity against the adult parasites and use of these anthelmintics often requires repeated treatments, which are not always carried out in the field ([@bib0195; @bib0485]).

Vaccines, on the other hand, are considered safe and are acceptable to both users and consumers. New vaccine technologies and adjuvant development are further improving food safety by ensuring that these leave no residues in food ([@bib0435; @bib0005]). As no chemical residues are passed onto pasture, vaccines are also considered environmentally friendly. However, despite the huge successes we have made in vaccine development against viruses and bacteria over the past 200 years (and in recombinant vaccines in the last 30 years), with the exception of the live attenuated Huskvac vaccine for lungworm, there are no commercially viable vaccines for animal (or human) helminth parasitic pathogens. More recently, a new vaccine for *H. contortus*, Barbervax, consisting of native gut-derived antigen complex has been launched in Australia ([www.barbervax.com.au](http://www.barbervax.com.au/){#intr0010}).

3. Liver fluke disease: a food-borne zoonotic disease {#sec0015}
=====================================================

Liver fluke disease, or fasciolosis, in sheep and cattle results from infection with the trematode, *F. hepatica* ([@bib0035]). Due to the emergence of parasites resistant to the frontline drug triclabendazole (TCBZ) and also to climate changes favourable to the survival of the intermediate host (*Galba truncatula*) and the infective stage (metacercariae) of the parasite ([@bib0480]), consistently high prevalence levels of liver fluke have been recorded across Europe (recently reviewed by [@bib0080]). Within the UK, the prevalence of fasciolosis has shown a marked increase, specifically in dairy herds from 48 to 72% from 2003 to 2006 ([@bib0350]) and, more markedly, the distribution of liver fluke has spread to include areas of Scotland and East Anglia ([@bib0495; @bib0290]). The increased prevalence of *F. hepatica* further adds to the economic impact of this parasite and indicates that the potential losses are greatly under-represented.

*F. hepatica* is also an important pathogen of humans in certain regions of the world where farm management practices allow infected animals to roam amongst vegetation consumed by humans. Global human infections are estimated to be between 2 and 17 million with 180 million people at risk; prevalence is particularly high in the Andean Altiplano (Bolivia, Peru and Ecuador) with lower infection numbers recorded in Egypt, Iran and South East Asia ([@bib0335; @bib0345; @bib0235]). The widening geographical distribution of liver fluke also has an impact on human infections, with fasciolosis recently being reported in areas of Pakistan ([@bib0015]). Besides better farm management procedures, control of human infections would greatly benefit from a vaccine targeting animal infections.

The discovery of novel means of control and intervention for fasciolosis requires us to be cogniscent of each stage of the parasite\'s life cycle and interpret this as a complex interplay between parasite and host. Parasite stages termed cercariae are released by snails that encyst on grass and other vegetation as metacercariae, which can survive for up to a year ([@bib0035]). Following ingestion by grazing animals, the parasites emerge from their cysts in the intestine (we term these newly excysted juveniles, NEJ), traverse the intestinal wall, which takes just a few hours, before migrating through the liver capsule and into the parenchyma. Here their feeding and migratory activities cause tissue perforation and haemorrhage, leading to extensive tissue damage. After about 7--8 weeks, the parasites migrate into the bile ducts, mature and produce 20,000--24,000 eggs per fluke per day which are released onto the pasture with the faeces ([@bib0065]). Following embryonation on pasture, the eggs hatch and release motile miracidia that infect mud snails and initiate another cycle of infection.

The liver damage caused by these migrating parasites reduces animal performance, fertility and wool and milk production (reviewed by [@bib0555; @bib0385; @bib0295; @bib0040; @bib0080]). These injurious pathogenic effects are compounded by the negative impact the parasite has on the immune system; potent immunosuppressive molecules secreted by the parasite compromise the natural resistance of the host and promote co-infections resulting in microbial diseases such as salmonellosis, clostridiosis and tuberculosis ([@bib0020; @bib0025; @bib0245; @bib0070; @bib0205; @bib0210; @bib0120]). The parasites can live for very long periods (longest recorded 11 years in sheep; [@bib0170]) inflicting long-term damage, causing low performance ([@bib0480]) and possibly reduced ability to resist other infections.

4. *F. hepatica*-induced tissue damage and the immune response: partners in hepatic pathology {#sec0020}
=============================================================================================

The early pathogenesis of fasciolosis involves two stages. A pre-hepatic stage is caused by the penetration of NEJ through the host intestine wall and migration within the peritoneal cavity, which lasts for approximately 3 days after the primary infection ([@bib0285]). Animals display no clinical signs at this time and pathological findings are rare, except for small haemorrhagic foci in the peritoneum layer. No changes are observed in the intestine wall ([@bib0285; @bib0065; @bib0280; @bib0645; @bib0650]), which suggests that the parasite moves swiftly through this tissue and/or possesses a mechanism that suppresses immune activation within the tissue. However, the parasites clearly induce an 'immunological presence' as the cellular component of the peritoneal fluid does change, with the infiltration of a large number of immune cells such as lymphocytes, macrophages and, especially, eosinophils ([@bib0645; @bib0650]). Control of the host immune system by *F. hepatica* likely begins here as experiments in laboratory animals have demonstrated that recruitment and activation of M2 macrophages is evident within 24 h after infection ([@bib0140; @bib0145; @bib0010]) and that flukes induce an apoptotic effect on peritoneal immune cells ([@bib0565; @bib0240]). This early immunomodulatory effect likely plays a critical role in determining the ultimate outcome of *F. hepatica* infection and is triggered directly by molecules (such as proteases, protease inhibitors and anti-oxidants) secreted from the parasite and by host molecules (alarmins) that signal tissue damage to stimulate immune repair mechanisms ([@bib0120]).

Between 4 and 6 days post-infection, the majority of NEJ have penetrated the liver capsule and established themselves firmly within the parenchymal tissue, which initiates the hepatic stage of pathogenesis. Depending on the definitive host, the time of migration from intestine to liver can extend up to 10 days ([@bib0135; @bib0595]). Here, the parasites move randomly, forming characteristic transects/tunnels and feed on the hepatic cellular components and blood for 5--6 weeks (parenchymal phase), before reaching the bile duct where they develop into their adult form (biliary phase) at 7--8 weeks post-infection ([@bib0570; @bib0150; @bib0550]). As a result of their parenchymal feeding activity, NEJ grow and develop rapidly, causing increased hepatic necrotic tracts and haemorrhaging resulting in acute and subacute fasciolosis.

The hepatic-stage histopathology is characterised by acute necrotic foci and tracts, some of which are associated with haemorrhages. In the early stages of infection, migrating NEJ are surrounded by relatively healthy hepatic parenchyma, whereas necrotic tracts and haemorrhages are found several millimetres behind the larvae, suggesting that products shed or released by NEJ are responsible for hepatic necrosis ([@bib0645; @bib0650]). Migrating larvae in sheep ([@bib0375]) and goats ([@bib0645; @bib0650]) are not surrounded by the inflammatory infiltrate, a feature which has been attributed to the rapid migration of NEJ ([@bib0375]). By contrast, in recent vaccine trials in goats, we found that animals showing little hepatic damage exhibited severe infiltration of eosinophils surrounding migratory flukes at early stages of infection ([@bib0645; @bib0650]). Necrotic hepatic tissue induces chemotaxis of inflammatory cells, particularly eosinophils, macrophages and lymphocytes, which are found at the periphery of necrotic areas. Macrophages become activated, increasing in size and accumulate around the necrotic areas in a palisade pattern, surrounded with lymphocytes to form necrotising granulomas ([@bib0325; @bib0645; @bib0650]). Small necrotic foci or tracts are phagocytosed and removed by activated macrophages, but larger necrotic areas are encapsulated by fibrous connective tissue, leading to tortuous fibrous scars (chronic tracts) after necrosis or haemorrhages are removed. Even in a single dose infection, it is common to find acute, subacute and chronic tracts in the liver due to the same larvae migrating for weeks, and thus the simultaneous migration of many immature forms can cause severe damage to the liver parenchyma. The clinical signs characterising this stage of infection include jaundice, ill-thrift and anaemia and can even result in death, particularly of young animals.

The presence of adult flukes within the bile ducts induces a severe chronic cholangitis with erosion and hyperplasia of the biliary epithelium, infiltrate of eosinophils, lymphocytes and plasma cells in portal areas, intraepithelial infiltration of globule leukocytes and portal fibrosis ([@bib0045; @bib0440; @bib0450; @bib0605; @bib0635; @bib0230]). These lesions, together with chronic tracts induced during the migratory stage, are typical of chronic fasciolosis ([@bib0445; @bib0635; @bib0645; @bib0650]). Chronic fasciolosis is the most common form in ruminants and occurs when the adults reach the bile ducts. Clinically, it is characterised by similar signs as the acute/subacute phase, together with persistent diarrhoea, pallor of mucous membranes, weight loss, weakness, with some animals developing oedema under the jaw ('bottle jaw') ([@bib0045]).

Adult flukes feed on blood and hepatic parenchyma adjacent to bile ducts, causing damage and focal rupture of bile ducts, allowing some parasite eggs to reach the liver parenchyma causing severe eosinophilic and granulomatous inflammatory responses ([@bib0450; @bib0445; @bib0635; @bib0645; @bib0650]). At this stage, it has been shown that in sheep, parasite excretory-secretory (ES) products continue to stimulate a favourable immune environment for parasite survival and induce apoptosis of inflammatory cells in the pericholangiolar inflammatory infiltrates (Escamilla et al., unpublished). The migratory behaviour of the parasite may be an immune evasion tactic as parasites are rarely found in the tracts themselves but have moved on leaving behind a trail of destruction. Lesions can also be found in the liver where parasites are absent, suggesting that antigens released by the parasite can become trapped in the tissue and attract immune cell infiltration.

A major factor that contributes to hepatic damage is the level of the infective dose. Previous studies revealed that, after high infective doses, the lesions found were more severe, even causing death of the animals during early infection, whereas under low infective doses the disease develops chronically ([@bib0045]). Moreover, studies carried out in sheep ([@bib0450]) and goats ([@bib0330; @bib0440]) have shown that small repeat infections, similar to those which occur in natural infections ([@bib0090]), produce more severe hepatic lesions than a single infective dose of equal metacercariae number. These findings suggest that, while the mechanical tissue-penetrating action of the parasite may be the cause of hepatic damage, it is the ensuing immune, or wound-healing, response that plays the major role in the pathology of fasciolosis. The immunopathological cells comprise T lymphocytes (CD4+, CD8+ and gamma-delta), B cells and macrophages, eosinophils and mast cells which lead to the formation of large granulomas ([@bib0085; @bib0330; @bib0440; @bib0450; @bib0445; @bib0640]).

Understanding how the immune system of various ruminant hosts leads to tissue damage following primary and subsequent infection with *F. hepatica* is still a huge challenge to researchers but is essential to lay the basis for effective vaccine development. Dissecting the myriad of cytokines, chemokines and innate and adaptive cellular pathways that are elicited to infection is critical to identify those that are responsible for protecting against infection whilst preventing excessive tissue damage. To date, we know that *F. hepatica* infection drives the host immune system towards an immunomodulatory response leading to the activation of T helper (Th) 2 immune response within 7 days of infection, with the concurrent production of high titres of IgG1 antibodies without IgG2 (sheep and cattle: [@bib0405; @bib0400; @bib0620] and murine models: [@bib0140; @bib0145]), and a down-regulation of Th1 immune response in murine models ([@bib0070; @bib0430]) and cattle ([@bib0210]). Thus, mouse studies indicate that while the parasites induce host hepatic damage, it has the ability to limit the extent of pro-inflammatory Th1-driven protective immune responses and promote anti-inflammatory healing mechanisms, involving a Th2-mediated immune response, M2 macrophages ([@bib0140; @bib0145]) and mast cells ([@bib0615]). Collectively, this prevents the development of a protective immune response against the parasite allowing the development of a chronic infection. It is possible that, similar to infections with schistosome parasites ([@bib0095]), the elaboration of an anti-inflammatory/regulatory immune response is important to protect the host from excessive immune-mediated liver damage ([@bib0365]). These anti-inflammatory immune responses may be effective in preventing host mortalities in low-level infections, but in high-level infections severe liver damage caused by the migrating flukes may overwhelm this protective response and cause organ failure. This proposal is important to consider for future vaccine development as their efficacy may be highly dependent on infection dose, or in a field/herd situation a vaccine may only be effective in animals that acquire low-level infections. More studies that investigate the effect of infection dose and repeated infection on host immune responses are needed to understand the impact of these schedules on liver tissue damage, immune-related pathology and the overall pathogenesis of liver fluke infection.

5. There is no strong evidence of protective immunity in ruminants to *F. hepatica* infection {#sec0025}
=============================================================================================

Compounding the difficulty of *F. hepatica* vaccine development is the lack of evidence for natural innate and cellular immune-mediated resistance in ruminants to these parasites (also reviewed by [@bib0470]). Few studies have directly addressed this question, though [@bib0090] have shown that cattle chronically infected in the field do not develop resistance to an experimental challenge. Studies by [@bib0160] attempted to identify the tissue where resistance to infection in cattle is mediated. While they found that cattle infected 18 or 26 weeks previously exhibited high levels of resistance to a secondary challenge infection (56 and 94%, respectively, assessed by fluke number 15/16 weeks after challenge infection), no protection was observed if they sacrificed animals earlier, at 4--14 days after the challenge infection. From this data, they suggested that resistance mechanisms were effective against the challenge infection after the parasites penetrated the liver capsule. However, whether these 'protective mechanisms' were immunologically mediated or result from tissue damage and fibrosis caused by the primary infection is open to debate. Indeed, early studies by [@bib0545], [@bib0060] and [@bib0165] suggested that protection in cattle to re-infection was related to tissue fibrosis caused by the primary infection which retards the migration of the parasites in the challenge infection; therefore, a high primary challenge leads to greater liver fibrosis and, consequently, seemingly greater protection compared to low primary infections. A more recent study by [@bib0250] has indicated that infections with TCBZ-drug abbreviated *F. hepatica* could induce a partial protective response as judged by measuring the serum levels of liver enzymes. However, this study was not supported by estimations of parasite burden and would need to be repeated to validate these suggestions.

The only commercially available vaccine for any ruminant helminth is Huskvac. This consists of radiation-attenuated 3rd-stage larvae and is highly effective against lungworm (husk) caused by the nematode, *D. viviparus* ([@bib0360]). Likewise, radiation-attenuated larvae (cercariae) of *Schistosoma mansoni* induce high levels of protection (which is transferable with antibodies and immune cells) against a heterologous parasite challenge infection in mice and non-human primates and is the basis of many approaches to vaccine development ([@bib0030; @bib0175; @bib0050]). Irradiation of *F. hepatica* metacercariae can attenuate the parasites; however, while parasites successfully excyst and the NEJ are capable of crossing the intestine and penetrating the liver tissue, they do not develop beyond the equivalent of 10-day-old normal parasites and, hence, they cause little pathology ([@bib0065; @bib0500; @bib0265]). Early studies by [@bib0130] in cattle have shown that high dose infections with radiation-attenuated parasites did not confer any resistance to a challenge infection. In experiments in which some protection was observed following immune priming with radiation-attenuated metacarceriae, protection was attributed to flukes that escaped attenuation, developed normally and induced liver pathology and fibrosis. Results of these experiments would argue that the early migratory stages of the parasite do not induce potent immunologically driven protective responses and that liver pathology/fibrosis is predominantly responsible for protection against challenge.

As recently discussed by [@bib0610], sheep appear to offer no immunological resistance to infection with *F. hepatica*, and even Indonesian Thin Tailed (ITT) sheep that elicit a protective innate and adaptive response to *Fasciola gigantica* are susceptible to infection with *F. hepatica*. Furthermore, while peritoneal cells removed from *F. gigantica*-infected ITT sheep (predominantly eosinophils and macrophages) mediate antibody-dependent cytotoxicity against *F. gigantica* NEJ *in vitro* by the production of superoxide radicals, this mechanism was ineffective against *F. hepatica* NEJ ([@bib0465]). These studies suggest that *F. hepatica* NEJ possess a unique ability to resist killing by reactive oxygen species released by sheep innate immune effector cells, which may involve the high expression of antioxidant enzymes such as superoxide dismutase, glutathione *S* transferase (GST) or peroxiredoxin ([@bib0475; @bib0465; @bib0140; @bib0145]). Sheep do not develop such a marked fibrotic reaction in the liver parenchyma or calcification of the bile ducts compared to cattle infected with *F. hepatica* (reviewed by [@bib0045]) leaving them highly susceptible to disease which can be fatal at high doses. From a vaccine perspective, the differences between cattle and sheep immune responses are important to delineate. In particular, while the targets at which the vaccine may be directed could be the same for cattle and sheep, the formulation, delivery regime and administration methods may need to be tailored to elicit efficacious immune responses in each species.

We propose that infection of ruminants with *F. hepatica* induces potent immune suppression or modulation to an extent that animals are susceptible to further infection with liver flukes (and other pathogens). The developing Th2-driven immune response, and suppressed Th1 response, that lead ultimately to an immune regulatory environment, may be necessary to secure parasite survival and at the same time prevent excessive immune-mediated damage to the liver (particularly by containing the damage within the parasite tracts, and laying down fibrotic tissue). However, this immune response may not be sufficient to prevent death resulting from organ failure caused by high-level or repeated infections. It follows that future vaccine programmes need to target parasite molecules that are involved in early stage migration, tissue penetration and immune evasion/suppression.

6. Vaccine candidates {#sec0030}
=====================

The recent review by [@bib0610] has summarised our progress in vaccine development against *F. hepatica*, and the related parasite *F. gigantica*, over the last three decades. Interestingly, most of the vaccine candidates were first isolated as native proteins, usually from adult worm ES products, because this antigen preparation was not very complex and was easy to obtain. Several of these early antigens, including cathepsin L proteases, GST and fatty acid binding protein (FABP) induced significant protection in cattle and sheep (reviewed by [@bib0610]), reducing not only worm burden (and egg output), but also liver pathology. Recent reports of vaccine trials in sheep with several recombinant but functional forms of these antigens such as cathepsin L1 (CL1), GST and peroxiredoxin (FhPrx) from *F. hepatica*, or Sm14 peptide from *S. mansoni*, have not reported significant reduction of worm burdens but have shown reduced liver pathology ([@bib0460; @bib0640; @bib0645; @bib0650; @bib0380; @bib0455; @bib0305; @bib0610]). While enthusiasm for bringing these antigens forward as future vaccines has waned largely because of inconsistency of vaccine results (such as with GST and cathepsin L, see [@bib0590; @bib0610]), in our opinion, there has not be an exhaustive assessment of these antigens in terms of formulation and delivery (as well as combination vaccines) and, hence, we would disagree with [@bib0610] in dismissing molecules such as GST and FABP as potential future vaccines because of the discrepancy between available data. Furthermore, recent genomics/transcriptomic data reveal these proteins belong to large families with complex developmental expression patterns (Cwiklinski et al., unpublished) that need to be explored further to ensure that the appropriate member(s) are those that are brought into vaccines trials. The observation that adult worm-derived antigens can induce protection at the level of the liver (and possibly earlier) would suggest that these antigens are either also expressed by the juvenile/immature parasite stages or that the immune response cross-reacts between the various members of the same family. If the latter scenario is the case, then perhaps focusing on family members that are expressed by the early stage parasites would prove more promising.

Encouraging results from schistosome vaccine trials has shown that utilising combinations of antigens can increase the efficacy of vaccines ([@bib0415]). [@bib0415] showed that using a triple antigen vaccine with a combination of Sm14, IrV5 and ECL antigens, showed the highest level of protection when compared with single antigens alone. Similar studies have also recently been carried out using a multi-antigen approach for the nematode parasites, *H. contortus* ([@bib0580; @bib0310]) and *T. circumcincta* ([@bib0425]) with promising results suggesting that a vaccine combination approach may be the only way to combat these complex parasites, including *F. hepatica*.

7. Cathepsins L and B proteases: important to the parasite and prime vaccine targets {#sec0035}
====================================================================================

*F. hepatica* relies on proteolytic activity for many of its pivotal functional activities in the host, including tissue penetration, migration, feeding and immune evasion and, hence, it is not surprising that these have been the most encouraging candidates for vaccine development for some time ([@bib0120]). Adult parasites secrete an abundance of cathepsin L cysteine proteases, representing about 80% of the total protein from adult ES, that they use for digesting the protein contents of the blood, including haemoglobin, albumin and immunoglobulin, consistent with ES protein analysis ([@bib0625]). This provides free amino acids required for synthesising egg proteins ([@bib0525]). Native cathepsin L proteases are readily isolated from adult ES products by standard gel permeation and ion exchange chromatography into two 'homogeneous' fractions (termed FhCL1 and FhCL2) ([@bib0575; @bib0155]). The highly significant protection (regularly 50--55% reduction in worm burden and egg production) observed using these native preparations when delivered in Freund\'s complete adjuvant was further enhanced (72.4%) when combinations were made with proteins contained in a high molecular weight haem-containing (Hb) fraction. The Hb fraction itself induced low but significant protection (43.8%) in cattle against a challenge infection and recent proteomic analysis has revealed that this mixture includes peroxiredoxin (FhPrx), the helminth defense molecule (FhHDM) and fatty acid binding protein (FABP), all of which can induce modulation of host immune responses including alterations in macrophage function ([@bib0530; @bib0515; @bib0600; @bib0120; @bib0200]). In sheep, a combination of the FhCL1 and FhCL2 induced 60% protection but were less efficacious when used individually (34 and 33%, respectively). Surprisingly, neither FhCL1 nor FhCL2 enhanced the efficacy of *F. hepatica* leucine aminopeptidase, which alone was highly efficacious (89%) in sheep ([@bib0460]).

Our understanding of *F. hepatica* proteases, and other secreted proteins, has been greatly improved by the availability of proteome data ([@bib0275; @bib0395; @bib0540; @bib0535]) and by integrating this with an analysis of the transcriptome ([@bib0535]). We now know that FhCL1 and FhCL2 are not expressed and secreted by the NEJ as they penetrate the liver and intestine; these early-stage parasites produce different members of the cathepsin L family, FhCL3 and FhCL4. FhCL3 is particularly abundant and secreted by NEJ while FhCL4 may play a more housekeeping role ([@bib0075; @bib0540; @bib0535]). The expression of FhCL3 is down-regulated soon after the parasite enters the liver parenchyma while FhCL1, FhCL2 and another family member, FhCL5, become more predominant as the parasite migrates and prepares to enter the bile ducts. These changes in protease expression reflect the parasite\'s adaptation to its changing environment as it migrates through different tissues and encounters new macromolecules. Molecular and biochemical analysis of FhCL3 ([@bib0105; @bib0110; @bib0520]) have shown that this enzyme possesses a constellation of residues in its active site that confer it with a unique ability to digest collagen, suggesting that this protease is critical to parasite penetration of the intestine and liver capsule ([@bib0125]). Once within the liver parenchyma FhCL2, which also exhibits collagenolytic activity (albeit, not are effective as FhCL3), together with FhCL1 and FhCL5, which both lack collagenolytic activity ([@bib0520]), combine to generate an efficient tissue-degrading and feeding mechanism. Once in the bile ducts, the parasites rely most heavily on FhCL1 which has an active site arrangement that gives this protease a marked preference for cleaving peptide bonds involving residues (Leu, Ala and Phe) that are common in haemoglobin and, hence, appears to be specifically adapted to blood feeding ([@bib0315]).

Interestingly, a similar highly regulated pattern of expression occurs with the cathepsin B proteases. Several cathepsin B proteases (FhCB1, FhCB2 and FhCB3) show parallel expression with the FhCL3, i.e. are secreted by the early NEJ but are down-regulated as the parasite migrates in the liver tissue. This would suggest that the concerted action of FhCL3/FhCBs is essential for successful intestine and liver penetration. In support of this suggestion, [@bib0355] demonstrated that RNAi-mediated knockdown of either the NEJ FhCLs or FhCBs blocked their ability to traverse the intestine wall. Once in the liver, the parasite cathepsin B proteases (FhCB1, FhCB2 and FhCB3) are switched off but, in contrast to the cathepsin Ls, are not replaced by other family members (other members exist but present studies indicate that these are not secreted and may play a role in the internal tissues/cells of the parasite). It appears that the role of liver migration, tissue feeding and then blood digestion while residing in the bile ducts is the sole responsibility of the FhCL1, FhCL2 and FhCL5.

The exquisite control of the expression of the cysteine proteases as the parasites migrates and establishes a long-lived infection in the host is now guiding our strategy for vaccine development. Given that partial protection against infection can be achieved in ruminants by vaccination with a single recombinant protease such as FhCL1, which is predominantly secreted in the bile duct, it may be judicious for sheep and cattle vaccines to combine this with other family members, most particularly FhCL3, or with members of the cathepsin B family (FhCB1, 2 or 3), that are more specifically expressed in the early juvenile stages. Experiments in rats achieved a level of 83% protection by combining FhCB2 with FhCL5 ([@bib0270]).

8. Future direction using next-generation technologies {#sec0040}
======================================================

Following the development and advancement of next-generation sequencing technologies, large sequence data sets are now being generated for several parasites ([@bib0260; @bib0225; @bib0630; @bib0220]). Genome data sets can inform functional genomics analysis, including transcriptomics, proteomics, secretomics and epigenomics. Utilising all available 'omics' data for a particular parasite provides an unbiased approach to understanding parasite biology, rather than focusing on a particular gene or protein. Furthermore, we can now perform in-depth analysis of the structure and expression of complex gene families. This will provide a comprehensive understanding of which genes/proteins are important at each stage of development, especially those acting at the host--parasite interface, which are of potential importance for invasion and infection. Furthermore, we are now beginning to probe the interfaces between the host and parasite and monitor their dynamics. Accordingly, those molecules released by the parasite into the host tissues either as soluble mixtures ([@bib0540; @bib0535]) or part of the cargo of vesicles/microparticles ([@bib0320]) have been reported. A detailed characterisation of the fluke surface tegument has also been carried out ([@bib0625; @bib0610]) which may also be exploited as vaccine and diagnostic targets ([@bib0490]). Reverse genetics tools such as RNAi can be used for *F. hepatica* and currently represents a most direct means to investigate the functionality of NEJ proteins ([@bib0355; @bib0505; @bib0370]).

Recently, a draft *F. hepatica* genome has been completed together with extensive transcriptome datasets for several lifecycle stages, NEJ (1-, 3- and 24-h post-excystment), 21--day-old juveniles and mature adult flukes (Cwiklinski et al., unpublished). Using clustering analysis, genes exhibiting similar temporal expression patterns have been grouped to provide a more complete picture of which genes are important at each stage of development, which will allow us to investigate how the functions are inter-connected. For example, when this analysis was applied to cathepsin L and cathepsin B genes, it supported our previous findings regarding their strict developmental regulation as described above, as well as providing a more detailed and reliable clarification of the gene family members. Exploiting this cluster analysis will allow the development of a framework from which a multi-antigen vaccine programme targeted towards a specific lifecycle stage or several stages can be implemented.

The extensive sequencing carried out for several *F. hepatica* isolates has also revealed that these helminths are highly polymorphic and, therefore, likely to be highly adaptable (Cwiklinski et al., unpublished). In particular, the high level of genetic diversity could explain the emergence of anthelmintic resistance in diverse *F. hepatica* populations across the world and should influence future control strategies, using drugs and/or vaccines. Anthelmintic resistance is likely to be multi-genic, and possibly involving different genes each time resistance evolves in different fluke populations across the world, which poses several questions regarding how data from different fluke populations can be interpreted. Will different parasite populations, even within similar geographical locations, respond differently to new drug and vaccine control strategies? Is the inconsistency observed in vaccine trials (inter- and intra-laboratory) due to the use of different fluke populations or genetic variation within populations? Potential variations between fluke populations need to be considered for any control strategy and, more relevantly, suggest that a multi-antigenic approach to vaccine development may have a better chance of succeeding.

9. Conclusion {#sec0045}
=============

Over the last few decades, much progress has been made in the isolation, characterisation and testing of a number of native and recombinant molecules as vaccines against liver fluke disease in ruminant hosts ([@bib0610]). Despite significant success, however, data between trials, even within the same laboratories, have shown a large degree of inconsistency. Much of this could be attributed to variations in a number of elements within the protocols employed, including vaccine schedules and formulations, age of animals, breed of animals, number of animals within groups, infection doses and infections regimes. Indeed, it is important that as we move forward within the research field, a standardised vaccine protocol is established to allow comparison of results between trials. For the same reason, as new immunological reagents become available to improve our analysis of ruminant immune responses, it is critical that we develop standard operation procedures (SOPs) for both sheep and cattle, and other species.

Fasciolosis is a hepatobiliary disease and, therefore, dysfunction of liver is the predominant physio-pathological complication that affects the total health status of the animal. This damage is caused directly by the parasite\'s migratory activity and indirectly by the host\'s immune response to parasite-secreted molecules and tissue damage. Therefore, reduction of the magnitude of the pathological damage by vaccinations may be as significant as reducing worm burden. While fluke burden and liver damage are likely to be interrelated, judging vaccine efficacy solely by enumerating fluke burden may not provide an overall accurate assessment of the benefit of a vaccine. Many vaccine trial protocols involve sacrificing animals at the chronic stage of infection when the challenge parasites are in the bile ducts and easily recovered. However, at this time point, liver damage cannot be easily graded as it contains both acute- and chronic-associated damage. Perhaps, we should consider placing a greater importance on diagnostic methods of hepatic pathology, so that protection against liver disease at early stages of infection can be quantified: such as estimating liver enzymes in serum (aspartate transaminase: AST, alkaline phosphatase: ALP, gamma-glutamyl transferase: GGT and glutamate dehydrogenase: GLDH) or finding novel serum biomarkers, such as the study by [@bib0510] that indicates several serological markers could be used for assessing liver damage.

The pursuit of a *F. hepatica* vaccine needs to focus on understanding fluke biology, specifically the proteins involved in the tissue invasion and migration within the definitive host. It is our opinion that the most effective vaccine would be one that is directed against the early migratory stages of the parasite, including surface tegumental proteins/glycoproteins and secreted molecules, with the primary aim of preventing the penetration of the liver capsule by the parasites. However, other vaccine strategies may include targeting those molecules that suppress the development of Th1-mediated immune responses, those antigens that induce liver damage and/or attract the infiltration of immune cells or, indeed, the sensory molecules that facilitate the migration of the fluke from intestine to liver to bile duct. This presents us with the challenge of learning more about the early migratory stages of *F. hepatica*, a stage that has traditionally been neglected, particularly in ruminants, due to the difficulty of obtaining workable levels of parasite material. However, genomic, transcriptomic and proteomic methods have made the molecular dissection of this parasite stage possible and will facilitate the rational design of single and multiple antigen vaccine cocktails. It is imperative that we bolster this molecular progress with new methodologies and by combining robust immunological analysis of innate and adaptive responses with pathological analysis of the early stages of infection to understanding how and when the parasite initiates control of host immune responses.

Finally, translating experimental findings to the field will throw up many challenges including issues related to parasite polymorphism as described above. Also, developing effective vaccine formulations that will induce potent protection in the field with low antigen dose and the minimum number of injections (preferably two or less) will be required to make these commercially viable. Nevertheless, field trials will provide valuable information of vaccine performance (e.g., potency and longevity) at a 'herd' level where infection rates can vary significantly between animals and will help answer the critical question of whether vaccinating is more beneficial or financially worthwhile than not vaccinating to the end-user, i.e. farmers. Clearly, we are not there yet but the road ahead looks very promising.
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